Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Thursday. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01), Bloomberg Earnings reports. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/02/karyopharm-therapeutics-inc-kpti-announces-earnings-results.html.

A number of research analysts have commented on the stock. ValuEngine upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. BidaskClub upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $15.38.

In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the sale, the director now owns 2,882 shares of the company’s stock, valued at approximately $31,702. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 10,695 shares of company stock worth $118,950. Corporate insiders own 14.71% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.